1.Novartis have played a major role in the pharmaceuticals industry over the years.

This
company had a great vision how to grab the market and make a change that can kicks-off a
journey in the medical history. The deep sequencing of human genome and how inexpensive that
has become created a wealth of data that will allow new areas of discovery that have never been
possible before.
With the advent of modern technology, Novartis has made some significant changes and develop
innovative new medicines in those areas. As people age, their muscle loss become very common,
and hearing loss. Technology allows to contribute in the development of new medicine and
overcome those problems people face.
Novartis CEO thinks that. bioinformatics capability is very important, as is the ability to mine
the data and really understand. In addition to, IT has become a crucial part of drug discovery. In
future, meld medical, technologies will be needed to create a medical advancement.One bright
spot for years to come is the biogeneric drugs sector, which will be one major source of revenue,
and a strong engine for future growth for Novartis.
However, the growth of health care spending cannot continue the current rate. So, novartis have
to think other way. Because solid financial footing is necessary if someones is willing to make
the wheel moving. Novartis only aim is to develop new and innovatinve medicines that can foucs
and change the practice of medicine in certain disease areas, so that those drugs will be
reimburesed.These drugs remain controversial, and present no approval clear pathway in the
USA yet, due to their recent introduction to the market and some other difficult issues. They are
developed at a lower cost for the drug company and will result in savings for the patient also.
Novartis has that way of pursing medical breakthrough, getting to blockbuster drugs, which is
quite different than the other companies. So , they started that approach a decade ago what they
called a pathway approach. That is used to understand the molecular pathway of particular
disease, usually in a rare disease that have a homegeneous patient population.
Novertis thought about this matter technically different from others. Homegeneous patient
population allows to study disease and molecular pathway that leads to that disease. Then they
developed a drug, which can interrupt that pathway and mechanistically expand their disease
area that are impacted by the same pathway. But it does not mean that blockbuster will go away,
1

An example has been given by the CEO of Novartis Joe Jimenez, about their oncology drug
called Afinitor, which is a mTOR inhibitor. This Mtor is implicated in different types of disease.
So, they had the idea to develop Afinitor in renal cell cancer and then testing this Afinitor in
diffrent types of cancer. Breast cancer was another indication they had received approval for,
which helped around thousand of patient every year. Thus, from one to another ther have just
expanded it. That together made a blockbuster.
Like others, Novartis had a plan to invest in the research and development process (R&D). But
Novastis CEO had quite different plan than others. They focus on the place, people to build their
research center. To find out world best scientist and researcher they placed their center in the
developed countries. Novartis made the committment of spending 20% of their sales to R&D
sector. And they did it perfectly. Joe made it clear that, talent and knowledge of spending was his
1st part of success. Afterwards, he realized pathway approach would be best among those
approaches and how they are going to develop and discover drugs.
Considering demographic factors and and goverment spending behaviour made it easier for
Novartis to increase the size of the market and improve its condition. However, Chinese were
spending most of the medical expenses out of their pocket. But the innovative drugs compelled
them to spend more without any hesitation. Apart from this growth story Novartis started to think
about the less priviledge country where people do not get enough medication to survie. Even
though their economic growth is 6% to 7% per year. Lack of infrastructure made it harder for
them to establish business and provide service on the remote area. Still, Novartis can vision a
temendous growth opportunity in Africa.
Novartis committed to support ethical clinical research; new global guidelines emphasizing the
principles of ethics, governance and transparency
- Clinical research conducted by qualified independent investigators is an important part of drug
discovery and development and can help explore unmet medical needs

Novartis CEO spent most of his career in consumer product. But working on a diffent kind of
industry was challenging and interesting too and advised others to to play to ones strength.
Though it was quite challenging for them to compete with the other established pharmaceutical.
They managed it properly to get along with different kinds of diffucult situations which led them
to success.
The Novartis case arguably sets an important precedent for the global pharmaceutical industry
andideally will help improve access to lifesaving medicines in the developing world by
demanding that patient healthneeds supersede commercial interests.
After doing all these hard work,Novartis saw the face of success. And thats how Novartis
innovated the new market.

2.Recommendation
Novartis has done a great job so far. They have created a successful company by delivering
quality drugs and services to customes. Medicine industry have seen a serious change in that
decade. Novartis has done a phenomenal job and brings changes to the medical industry. eing a
pharmaceutical company with advanced technology, Novartis has a lot of prospects to contribute
to the industry of pharmaceutical and biomedical sciences.
At the outset, Novartis converge part of its attention into research and early development of
treatments against neglected diseases. Novartis Institute for Tropical Diseases new research
centre was established and is solely dedicated for researches on dengue fever, malaria and drugresistant.
Apart of that, diabetes being the fourth leading cause of death globally, Novartis addressed the
issue by providing innovative therapies for diabetes treatment.
Holistically, this company became a factor in improvising the worlds health by developing in
these areas; pharmaceuticals, vaccines and diagnostics, Sandoz and consumer health.
As for Novartis which has an extensive involvement in research and development, innovation in
technology would affect the business and development to the highest degree.
Understanding this, Novartis has always been ensuring that the instrumentations as well as
pipelines of theirs are brought up to date from time to time with the maximum efficiency to
enhance the productivity of the company.
Novartis International AG has a well-defined framework in all the different aspects which is
consent to a pharmaceutical company. With clear and distinct mission and core competencies, the
management has empowered the associates take on investing ideas and work for the company. It
is also commendable that as of now, Novartis being a MNC has complement with all the
different countries legislations in manufacturing drugs and carrying out researches.
Nevertheless, there are some recommendations that Novartis could implement in order to shape
an even better pharmaceutical company with excellent progress in business and development. At
4

the outset, Novartis should review and restructure (if necessary) the proportion of focus that has
to be given to the different sectors in this company. As of now, Research and Development sector
has been prioritized too much. In latter stages, there may be a possibility for Novartis to
encounter high rate of discontinuation in pre-approval products.
Apart of that, I also recommend Novartis to focus on resources management. One of the
implementation that they can uphold is to analyse their resources well and identify the rate of
resource wastage. As soon as they have recognized this factor, they would be able to
systematically distribute the resources for future researches.
In conclusive, I would like to quote that Novartis International AG has the potential to develop to
be the worlds largest pharmaceutical company if they have employed a better marketing strategy
and a comprehensive review system in all the aspect that would affect their business and
development.